Publication | Closed Access

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

GliomaMedicinePharmacologyNeuroendocrine DisorderCancer TreatmentAdvanced Neuroendocrine TumoursOncologyRadiation OncologyNuclear MedicineEndocrine-related CancerPre-therapeutic Dosimetry86Y-dota-phe1-tyr3-octreotide Versus